Rodríguez B, Burguera J, Berenguer M

Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 907-914
Archivo PDF: 90.00 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. SAK W. Progressive lenticular degeneration: a familiar nervous disease associated with cirrosis of the liver. Brain 1912; 34: 295-507.

2. Saito T. An assessment of efficiency in potential screening for Wilson’s disease. J Epidemiol Community Health 1981; 35: 274-80.

3. Bull PC TG, Rommens JM, Forbes JR, Cox DW. The Wilson Disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-37.

4. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993; 197: 271-7.

5. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-50.

6. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype- phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61: 317-28.

7. Scheinberg IH, Sternlieb I. Wilson’s Disease. Annu Rev Med 1965; 16: 119-34.

8. Brewer GJ. Recognition, diagnosis, and management of Wilson’s disease. Proc Soc Exp Biol Med 2000; 223: 39-46.

9. Sternlieb I. Diagnosis of Wilson’s disease in 1981. Gastroenterol Clin Biol 1981; 5: 169-74.

10. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139-42.

11. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007; 56: 115-20.

12. Maytum WJ, Goldstein NP, Mc GW, Owen CA Jr. Copper metabolism in Wilson’s disease, Laennec’s cirrhosis and hemachromatosis: studies with radiocopper (Cu64). Proc Staff Meet Mayo Clin 1961; 36: 641-60.

13. Saito H, Watanabe K, Sahara M, Mochizuki R, Edo K, Ohyama Y. Triethylene-tetramine (trien) therapy for Wilson’s disease. Tohoku J Exp Med 1991; 164: 29-35.

14. Walshe JM. Management of penicillamine nephropathy in Wilson’s disease: a new chelating agent. Lancet 1969; 2: 1401-2.

15. Walshe JM. Wilson’s disease; new oral therapy. Lancet 1956; 270: 25-6.

16. Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson’s disease (hepatolenticular degeneration). Eur Neurol 1979; 18: 205-11.

17. Schilsky ML, Blank RR, Czaja MJ, Zern MA, Scheinberg IH, Stockert RJ, Sternlieb I. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84: 1562-8.

18. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. Treatment of Wilson’s disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998; 132: 264-78.

19. Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson’s disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77: 137-46.

20. Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140: 1189-1198, e1.

21. Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142: 385-90.

22. Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson’s disease. Liver Transpl 2002; 8: 962-7.

23. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089-111.